Mitochondrial-targeted SS-31 (elamipretide) attenuates doxorubicin-induced H9C2 cardiomyoblast senescence
Background
Doxorubicin (DOX) is a highly effective chemotherapeutic agent, but its clinical utility is severely limited by dose-dependent cardiotoxicity, which can lead to irreversible heart failure. A key mechanism underlying DOX-induced cardiotoxicity is cell senescence, characterized by cellular dysfunction and the release of pro-inflammatory factors. Current treatments for DOX-induced cardiotoxicity are insufficient, highlighting an urgent need for novel cardioprotective strategies. This study explores the potential of SS-31, a mitochondrial-targeted tetrapeptide, to mitigate DOX-induced senescence.
Study Design
Researchers established an in vitro model of DOX-induced senescence using H9C2 cardiomyoblast cells. Cells were treated with 100 nM DOX for 3 hours to induce senescence, or 50 nM DOX for 3 hours followed by 3 days of culture to assess concentration-dependent effects. Senescence was quantified using SA β-gal staining and cell growth rate. Further confirmation involved assessing cell hypertrophy, p16 and p21 expression, Senescence Associated Secretory Phenotype (SASP) markers, cell cycle analysis, and ROS production. The mitochondrial-targeted tetrapeptide SS-31 (elamipretide) 1 µM was then tested for its ability to attenuate 50 nM DOX-induced senescence.
Results
A 50 nM concentration of DOX induced ~50% SA β-gal staining and completely inhibited H9C2 cell growth. This DOX-induced senescence was further confirmed by markers including cell hypertrophy, increased p16 and p21 expression, elevated SASP markers, arrested cell cycle, and increased ROS production. Interestingly, 50 nM DOX also increased mitochondrial respiration. Translationally, SS-31 (elamipretide) 1 µM partially attenuated 50 nM DOX-induced SA β-gal staining from 51.4% to 35.8%. SS-31 also prevented increases in the p16, p21, and SASP markers and mitigated mitochondrial ROS production. Additionally, SS-31 reversed the 50 nM DOX-induced elevation of mitochondrial respiration. However, 1 µM SS-31 failed to prevent the cell cycle arrest induced by 50 nM DOX.
SS-31 (elamipretide) 1 µM reduced doxorubicin-induced
SA β-galstaining by 30.3% (from 51.4% to 35.8%).
Key Findings
- 50 nM doxorubicin induced ~50%
SA β-galstaining and completely inhibited H9C2 cell growth. - SS-31 (elamipretide) 1 µM partially attenuated DOX-induced
SA β-galstaining from 51.4% to 35.8%. - SS-31 prevented increases in
p16,p21, andSASPmarkers. - SS-31 mitigated mitochondrial
ROSproduction and reversed elevated mitochondrial respiration. - SS-31 did not prevent cell cycle arrest induced by 50 nM DOX.
Why It Matters
This study provides a robust in vitro model for studying doxorubicin-induced cardiotoxicity and identifies SS-31 as a promising therapeutic candidate. Mitochondrial-targeted SS-31 could serve as an adjunctive therapy to mitigate the severe cardiotoxic side effects of doxorubicin, potentially allowing for broader or higher-dose chemotherapy regimens. While this is an in vitro finding, it strengthens the rationale for investigating SS-31's cardioprotective effects in preclinical animal models and eventually in clinical settings. The focus on mitochondrial health highlights a critical pathway for intervention in chemotherapy-induced organ damage, suggesting that protocols incorporating mitochondrial support could be beneficial.
ss-31
elamipretide
doxorubicin
cardiotoxicity
cell-senescence
mitochondrial-dysfunction